Clinical trials of Kazakhstan's first coronavirus vaccine QazVac successful - developer
NUR-SULTAN. Sept 6 (Interfax) - The clinical trials of Kazakhstan's first coronavirus vaccine, QazVac, have been successful, General Director of the Kazakh Research Institute for Biological Safety Problems Kunsulu Zakarya said.
"According to our report - the report was prepared by our institute - the clinical trials of Kazakhstan's first vaccine, QazVac, have been successful. In case our report is approved by the National Center for Expertise of Medicines and Medical Products, we are writing an article for another leading international journal with a high standing to demonstrate the success of Kazakh science," Zakarya said at a press briefing in Nur-Sultan on Monday.
The final report on Phase III and all clinical trials of the QazVac vaccine has been submitted to the National Center for Expertise of Medicines and Medical Products, she said.
"It is being evaluated. We haven't received a conclusion just yet," Zakarya said.
As reported earlier, Phase III of the clinical trials of Kazakhstan's QazVac coronavirus vaccine took place at three clinics in Almaty and Taraz, involved 3,000 volunteers, and ended on July 9, 2021.
An article about the QazVac vaccine, including the results of Phase I and Phase II of the vaccine's clinical trials, was published in the EClinical Medicine medical journal of The Lancet Group on August 14, 2021.
Documents are being drafted and validation of the vaccine production technology is being carried out consistent with good manufacturing practice requirements in order to register the vaccine with the World Health Organization.
The QazVac coronavirus vaccine (formerly known as QazCovid-in) was developed by the Research Institute for Biological Safety Problems of the Committee of Science of the Kazakh Ministry of Education and Science.
Kazakhstan began vaccinating its residents with the domestic drug on April 26.